Cargando…

Utility of cerebrospinal fluid liquid biopsy in distinguishing CNS lymphoma from cerebrospinal infectious/demyelinating diseases

BACKGROUND: Distinguishing between central nervous system lymphoma (CNSL) and CNS infectious and/or demyelinating diseases, although clinically important, is sometimes difficult even using imaging strategies and conventional cerebrospinal fluid (CSF) analyses. To determine whether detection of genet...

Descripción completa

Detalles Bibliográficos
Autores principales: Iriyama, Chisako, Murate, Kenichiro, Iba, Sachiko, Okamoto, Akinao, Goto, Naoe, Yamamoto, Hideyuki, Kato, Toshiharu, Mihara, Keichiro, Miyama, Takahiko, Hattori, Keiko, Kajiya, Ryoko, Okamoto, Masataka, Mizutani, Yasuaki, Yamada, Seiji, Tsukamoto, Tetsuya, Hirose, Yuichi, Mutoh, Tatsuro, Watanabe, Hirohisa, Tomita, Akihiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10501233/
https://www.ncbi.nlm.nih.gov/pubmed/37501501
http://dx.doi.org/10.1002/cam4.6329
_version_ 1785106076286320640
author Iriyama, Chisako
Murate, Kenichiro
Iba, Sachiko
Okamoto, Akinao
Goto, Naoe
Yamamoto, Hideyuki
Kato, Toshiharu
Mihara, Keichiro
Miyama, Takahiko
Hattori, Keiko
Kajiya, Ryoko
Okamoto, Masataka
Mizutani, Yasuaki
Yamada, Seiji
Tsukamoto, Tetsuya
Hirose, Yuichi
Mutoh, Tatsuro
Watanabe, Hirohisa
Tomita, Akihiro
author_facet Iriyama, Chisako
Murate, Kenichiro
Iba, Sachiko
Okamoto, Akinao
Goto, Naoe
Yamamoto, Hideyuki
Kato, Toshiharu
Mihara, Keichiro
Miyama, Takahiko
Hattori, Keiko
Kajiya, Ryoko
Okamoto, Masataka
Mizutani, Yasuaki
Yamada, Seiji
Tsukamoto, Tetsuya
Hirose, Yuichi
Mutoh, Tatsuro
Watanabe, Hirohisa
Tomita, Akihiro
author_sort Iriyama, Chisako
collection PubMed
description BACKGROUND: Distinguishing between central nervous system lymphoma (CNSL) and CNS infectious and/or demyelinating diseases, although clinically important, is sometimes difficult even using imaging strategies and conventional cerebrospinal fluid (CSF) analyses. To determine whether detection of genetic mutations enables differentiation between these diseases and the early detection of CNSL, we performed mutational analysis using CSF liquid biopsy technique. METHODS: In this study, we extracted cell‐free DNA from the CSF (CSF‐cfDNA) of CNSL (N = 10), CNS infectious disease (N = 10), and demyelinating disease (N = 10) patients, and performed quantitative mutational analysis by droplet‐digital PCR. Conventional analyses were also performed using peripheral blood and CSF to confirm the characteristics of each disease. RESULTS: Blood hemoglobin and albumin levels were significantly lower in CNSL than CNS infectious and demyelinating diseases, CSF cell counts were significantly higher in infectious diseases than CNSL and demyelinating diseases, and CSF‐cfDNA concentrations were significantly higher in infectious diseases than CNSL and demyelinating diseases. Mutation analysis using CSF‐cfDNA detected MYD88 (L265P) and CD79 (Y196) mutations in 60% of CNSLs each, with either mutation detected in 80% of cases. Mutual existence of both mutations was identified in 40% of cases. These mutations were not detected in either infectious or demyelinating diseases, and the sensitivity and specificity of detecting either MYD88/CD79B mutations in CNSL were 80% and 100%, respectively. In the four cases biopsied, the median time from collecting CSF with the detected mutations to definitive diagnosis by conventional methods was 22.5 days (range, 18–93 days). CONCLUSIONS: These results suggest that mutation analysis using CSF‐cfDNA might be useful for differentiating CNSL from CNS infectious/demyelinating diseases and for early detection of CNSL, even in cases where brain biopsy is difficult to perform.
format Online
Article
Text
id pubmed-10501233
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-105012332023-09-15 Utility of cerebrospinal fluid liquid biopsy in distinguishing CNS lymphoma from cerebrospinal infectious/demyelinating diseases Iriyama, Chisako Murate, Kenichiro Iba, Sachiko Okamoto, Akinao Goto, Naoe Yamamoto, Hideyuki Kato, Toshiharu Mihara, Keichiro Miyama, Takahiko Hattori, Keiko Kajiya, Ryoko Okamoto, Masataka Mizutani, Yasuaki Yamada, Seiji Tsukamoto, Tetsuya Hirose, Yuichi Mutoh, Tatsuro Watanabe, Hirohisa Tomita, Akihiro Cancer Med RESEARCH ARTICLES BACKGROUND: Distinguishing between central nervous system lymphoma (CNSL) and CNS infectious and/or demyelinating diseases, although clinically important, is sometimes difficult even using imaging strategies and conventional cerebrospinal fluid (CSF) analyses. To determine whether detection of genetic mutations enables differentiation between these diseases and the early detection of CNSL, we performed mutational analysis using CSF liquid biopsy technique. METHODS: In this study, we extracted cell‐free DNA from the CSF (CSF‐cfDNA) of CNSL (N = 10), CNS infectious disease (N = 10), and demyelinating disease (N = 10) patients, and performed quantitative mutational analysis by droplet‐digital PCR. Conventional analyses were also performed using peripheral blood and CSF to confirm the characteristics of each disease. RESULTS: Blood hemoglobin and albumin levels were significantly lower in CNSL than CNS infectious and demyelinating diseases, CSF cell counts were significantly higher in infectious diseases than CNSL and demyelinating diseases, and CSF‐cfDNA concentrations were significantly higher in infectious diseases than CNSL and demyelinating diseases. Mutation analysis using CSF‐cfDNA detected MYD88 (L265P) and CD79 (Y196) mutations in 60% of CNSLs each, with either mutation detected in 80% of cases. Mutual existence of both mutations was identified in 40% of cases. These mutations were not detected in either infectious or demyelinating diseases, and the sensitivity and specificity of detecting either MYD88/CD79B mutations in CNSL were 80% and 100%, respectively. In the four cases biopsied, the median time from collecting CSF with the detected mutations to definitive diagnosis by conventional methods was 22.5 days (range, 18–93 days). CONCLUSIONS: These results suggest that mutation analysis using CSF‐cfDNA might be useful for differentiating CNSL from CNS infectious/demyelinating diseases and for early detection of CNSL, even in cases where brain biopsy is difficult to perform. John Wiley and Sons Inc. 2023-07-27 /pmc/articles/PMC10501233/ /pubmed/37501501 http://dx.doi.org/10.1002/cam4.6329 Text en © 2023 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle RESEARCH ARTICLES
Iriyama, Chisako
Murate, Kenichiro
Iba, Sachiko
Okamoto, Akinao
Goto, Naoe
Yamamoto, Hideyuki
Kato, Toshiharu
Mihara, Keichiro
Miyama, Takahiko
Hattori, Keiko
Kajiya, Ryoko
Okamoto, Masataka
Mizutani, Yasuaki
Yamada, Seiji
Tsukamoto, Tetsuya
Hirose, Yuichi
Mutoh, Tatsuro
Watanabe, Hirohisa
Tomita, Akihiro
Utility of cerebrospinal fluid liquid biopsy in distinguishing CNS lymphoma from cerebrospinal infectious/demyelinating diseases
title Utility of cerebrospinal fluid liquid biopsy in distinguishing CNS lymphoma from cerebrospinal infectious/demyelinating diseases
title_full Utility of cerebrospinal fluid liquid biopsy in distinguishing CNS lymphoma from cerebrospinal infectious/demyelinating diseases
title_fullStr Utility of cerebrospinal fluid liquid biopsy in distinguishing CNS lymphoma from cerebrospinal infectious/demyelinating diseases
title_full_unstemmed Utility of cerebrospinal fluid liquid biopsy in distinguishing CNS lymphoma from cerebrospinal infectious/demyelinating diseases
title_short Utility of cerebrospinal fluid liquid biopsy in distinguishing CNS lymphoma from cerebrospinal infectious/demyelinating diseases
title_sort utility of cerebrospinal fluid liquid biopsy in distinguishing cns lymphoma from cerebrospinal infectious/demyelinating diseases
topic RESEARCH ARTICLES
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10501233/
https://www.ncbi.nlm.nih.gov/pubmed/37501501
http://dx.doi.org/10.1002/cam4.6329
work_keys_str_mv AT iriyamachisako utilityofcerebrospinalfluidliquidbiopsyindistinguishingcnslymphomafromcerebrospinalinfectiousdemyelinatingdiseases
AT muratekenichiro utilityofcerebrospinalfluidliquidbiopsyindistinguishingcnslymphomafromcerebrospinalinfectiousdemyelinatingdiseases
AT ibasachiko utilityofcerebrospinalfluidliquidbiopsyindistinguishingcnslymphomafromcerebrospinalinfectiousdemyelinatingdiseases
AT okamotoakinao utilityofcerebrospinalfluidliquidbiopsyindistinguishingcnslymphomafromcerebrospinalinfectiousdemyelinatingdiseases
AT gotonaoe utilityofcerebrospinalfluidliquidbiopsyindistinguishingcnslymphomafromcerebrospinalinfectiousdemyelinatingdiseases
AT yamamotohideyuki utilityofcerebrospinalfluidliquidbiopsyindistinguishingcnslymphomafromcerebrospinalinfectiousdemyelinatingdiseases
AT katotoshiharu utilityofcerebrospinalfluidliquidbiopsyindistinguishingcnslymphomafromcerebrospinalinfectiousdemyelinatingdiseases
AT miharakeichiro utilityofcerebrospinalfluidliquidbiopsyindistinguishingcnslymphomafromcerebrospinalinfectiousdemyelinatingdiseases
AT miyamatakahiko utilityofcerebrospinalfluidliquidbiopsyindistinguishingcnslymphomafromcerebrospinalinfectiousdemyelinatingdiseases
AT hattorikeiko utilityofcerebrospinalfluidliquidbiopsyindistinguishingcnslymphomafromcerebrospinalinfectiousdemyelinatingdiseases
AT kajiyaryoko utilityofcerebrospinalfluidliquidbiopsyindistinguishingcnslymphomafromcerebrospinalinfectiousdemyelinatingdiseases
AT okamotomasataka utilityofcerebrospinalfluidliquidbiopsyindistinguishingcnslymphomafromcerebrospinalinfectiousdemyelinatingdiseases
AT mizutaniyasuaki utilityofcerebrospinalfluidliquidbiopsyindistinguishingcnslymphomafromcerebrospinalinfectiousdemyelinatingdiseases
AT yamadaseiji utilityofcerebrospinalfluidliquidbiopsyindistinguishingcnslymphomafromcerebrospinalinfectiousdemyelinatingdiseases
AT tsukamototetsuya utilityofcerebrospinalfluidliquidbiopsyindistinguishingcnslymphomafromcerebrospinalinfectiousdemyelinatingdiseases
AT hiroseyuichi utilityofcerebrospinalfluidliquidbiopsyindistinguishingcnslymphomafromcerebrospinalinfectiousdemyelinatingdiseases
AT mutohtatsuro utilityofcerebrospinalfluidliquidbiopsyindistinguishingcnslymphomafromcerebrospinalinfectiousdemyelinatingdiseases
AT watanabehirohisa utilityofcerebrospinalfluidliquidbiopsyindistinguishingcnslymphomafromcerebrospinalinfectiousdemyelinatingdiseases
AT tomitaakihiro utilityofcerebrospinalfluidliquidbiopsyindistinguishingcnslymphomafromcerebrospinalinfectiousdemyelinatingdiseases